<DOC>
	<DOCNO>NCT01096966</DOCNO>
	<brief_summary>This study evaluate efficacy safety Bupivacaine TTS ( Bupivacaine patch ) compare placebo patient chronic low back pain .</brief_summary>
	<brief_title>Study Efficacy Safety Bupivacaine TTS Patch Patients With Chronic Low Back Pain</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1 . Diagnosis chronic low back pain 3 month 2 . If take nonsteroidal antiinflammatory drug nonopioid analgesic , must regular , schedule dose least 4 week prior first visit intend remain stable dose agent study duration 3 . Pain intensity score great equal 5 10 first visit 4 . Able apply patch home 5 . Able willing complete daily pain intensity rating use electronic diary device duration study 6 . Females childbearing potential must agree use medically acceptable method contraception throughout study 1 . History , ongoing , alcohol drug abuse 2 . Positive drug test alcohol , illicit drug use opioids 3 . Primary diagnosis chronic low back pain due neuropathic pain 4 . History back surgery plan back surgery 5 . Use opioids within 2 week first visit study 6 . Previous ineffective use lidocaine patch 7 . Morbid obesity 8 . Moderate severe depression 9 . An open skin lesion within painful area patch apply 10 . Patients active resolve back pain litigation receive disability payment due chronic low back pain 11 . Pregnant breastfeeding female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>chronic low back pain</keyword>
</DOC>